Circulating MicroRNA-122 signature in nonalcoholic fatty liver disease and cardiovascular disease: A new endocrine system in metabolic syndrome

dc.creatorPirola, Carlos José
dc.creatorFernández Gianotti, Tomás
dc.creatorCastaño, Gustavo Osvaldo
dc.creatorSookoian, Silvia Cristina
dc.date.accessioned2019-09-30T18:45:49Z
dc.date.accessioned2022-10-15T03:20:20Z
dc.date.available2019-09-30T18:45:49Z
dc.date.available2022-10-15T03:20:20Z
dc.date.created2019-09-30T18:45:49Z
dc.date.issued2013-06
dc.identifierPirola, Carlos José; Fernández Gianotti, Tomás; Castaño, Gustavo Osvaldo; Sookoian, Silvia Cristina; Circulating MicroRNA-122 signature in nonalcoholic fatty liver disease and cardiovascular disease: A new endocrine system in metabolic syndrome; John Wiley & Sons Inc; Hepatology (Baltimore, Md.); 57; 6; 6-2013; 2545-2547
dc.identifier0270-9139
dc.identifierhttp://hdl.handle.net/11336/84829
dc.identifierCONICET Digital
dc.identifierCONICET
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4339428
dc.description.abstractTo the Editor: We read with great interest the article by Bala et al. about the role of circulating microRNAs (miRNAs) as markers of alcohol‐ and acetaminophen‐induced liver damage in a mouse model; the investigators concluded that circulating miR‐122 and miR‐155 may serve as biomarkers of liver injury and inflammation, respectively.
dc.languageeng
dc.publisherJohn Wiley & Sons Inc
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/https://doi.org/10.1002/hep.26116
dc.relationinfo:eu-repo/semantics/altIdentifier/url/https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep.26116
dc.relationinfo:eu-repo/semantics/altIdentifier/url/https://pubmed.ncbi.nlm.nih.gov/23111985/
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectMIRNA 122
dc.subjectENDOCRINE
dc.subjectNAFLD
dc.subjectCARDIOVASCULAR DISEASE
dc.subjectPLASMA
dc.titleCirculating MicroRNA-122 signature in nonalcoholic fatty liver disease and cardiovascular disease: A new endocrine system in metabolic syndrome
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:ar-repo/semantics/artículo
dc.typeinfo:eu-repo/semantics/publishedVersion


Este ítem pertenece a la siguiente institución